endometrial cancer
US FDA expands Jemperli (dostarlimab-gxly) plus chemotherapy approval to all adult patients with primary advanced or recurrent endometrial cancer as the first and only immuno-oncology-based treatment to show an overall survival benefit
August 5, 2024Research and Development GSK, Oncology, Reproductive health, endometrial cancer
PHILADELPHIA–GSK plc today announced the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab-gxly) in combination with carboplatin and paclitaxel (chemotherapy) …
GSK’s Jemperli accepted for review by EMA for endometrial cancer treatment
June 24, 2024Medical Communications EMA, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced that the European Medicines Agency (EMA) has accepted the application to expand the use of Jemperli (dostarlimab) …
AstraZeneca’s Imfinzi approved in US for endometrial cancer treatment
June 17, 2024Medical Communications AstraZeneca, Imfinzi, Oncology, chemotherapy, endometrial cancer
AstraZeneca has announced that the US Food and Drug Administration (FDA) has approved Imfinzi (durvalumab) in combination with carboplatin and …
GSK’s Jemperli accepted for FDA review for endometrial cancer treatment
April 24, 2024Medical Communications FDA, GSK, Oncology, endometrial cancer, sBLA
GSK has announced that the US Food and Drug Administration (FDA) has accepted its supplemental Biologics License Application (sBLA) for …
GSK shares data from phase 3 trial for Jemperli combinations for endometrial cancer treatment
March 18, 2024Research and Development GSK, Jemperli, Oncology, clinical trial, endometrial cancer, women's health
GSK has announced positive results from part 1 and part 2 of its RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial for Jemperli (dostarlimab) …
GSK’s Jemperli recommended by NICE for endometrial cancer treatment
March 5, 2024Medical Communications GSK, Jemperli, NICE, Oncology, endometrial cancer
GSK has announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of Jemperli (dostarlimab) …
GSK shares results for Jemperli plus Zejula combination of endometrial cancer treatment
December 18, 2023Research and Development GSK, Jemperli, Oncology, Zejula, endometrial cancer
GSK has announced positive results from a planned analysis of the second part of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which …
GSK’s Jemperli approved in EU as treatment for endometrial cancer
December 11, 2023Medical Communications EU, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced that the European Commission (EC) has granted marketing authorisation to Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy, …
GSK shares results from phase 3 RUBY trial of Jemperli for endometrial cancer treatment
October 30, 2023Medical Communications Cancer, GSK, Jemperli, Oncology, endometrial cancer
GSK has announced positive headline results from an analysis of part 1 of the RUBY/ENGOT-EN6/GOG3031/NSGO phase 3 trial which assessed …
GSK’s Jemperli approved for treatment of endometrial cancer
August 1, 2023Research and Development FDA, GSK, Jemperli, Oncology, dostarlimab, endometrial cancer
GSK has announced that the US Food and Drug Administration (FDA) has approved Jemperli (dostarlimab) in combination with carboplatin and …
GSK receives FDA file acceptance for Jemperli plus chemotherapy for treating endometrial cancer
June 6, 2023Research and Development GSK, Jemperli, Oncology, endometrial cancer, oncology
GSK has announced that the US Food and Drug Administration (FDA) has accepted the supplemental Biologics License Application (sBLA) for …
Extended use of breast cancer drug tamoxifen linked to increased endometrial cancer risk
July 9, 2018Research and Development, Sales and Marketing Cancer, breast cancer, endometrial cancer, pharma, tamoxifen
New evidence published in the British Journal of Surgery has indicated a troubling link between long-term use of the breast …
Latest content
FibroFind appoints Lee Borthwick as CEO
